Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.

11/4/24 1:22:14 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PTGX alert in real time by email

SC 13G/A 1 UnitedStates_13G__Protagonis.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) Protagonist Therapeutics Inc (Title of Class of Securities) Common Stock (CUSIP Number) 74366E102 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 74366E102 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 105,584 (7) Sole dispositive power 4,064,443 (8) Shared dispositive power 151,638 (9) Aggregate amount beneficially owned by each reporting person 4,216,081 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 7.15% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: Protagonist Therapeutics Inc Item 1(b) Address of issuer's principal executive offices: 7707 Gateway Boulevard, Suite 140 Newark, CA 94560-1160 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 74366E102 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 4,216,081 (b) Percent of class: 7.15% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 4,216,081 (b) Percent of class: 7.15% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 105,584 (iii) Sole power to dispose or to direct the disposition of: 4,064,443 (iv) Shared power to dispose or to direct the disposition of: 151,638 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acq

Get the next $PTGX alert in real time by email

Recent Analyst Ratings for

$PTGX

Date	Price Target	Rating	Analyst
11/5/2024	$58.00	Outperform	Wedbush
9/24/2024	$65.00	Buy	TD Cowen
9/9/2024	$60.00	Buy	Truist
10/30/2023	$32.00	Overweight	CapitalOne
5/25/2023	$30.00 → $40.00	Buy	Jefferies
8/25/2022	$21.00	Mkt Outperform	JMP Securities
2/11/2022	$55.00	Buy	BTIG
11/15/2021	$60.00 → $70.00	Market Outperform	JMP Securities

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for $PTGX

$PTGX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Wedbush initiated coverage on Protagonist Therapeutics with a new price target

TD Cowen initiated coverage on Protagonist Therapeutics with a new price target

Truist initiated coverage on Protagonist Therapeutics with a new price target

$PTGX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

President and CEO Patel Dinesh V Ph D gifted 1,000 shares, decreasing direct ownership by 0.19% to 513,415 units (SEC Form 4)

Chief Medical Officer Molina Arturo Md sold $78,108 worth of shares (1,906 units at $40.98), decreasing direct ownership by 4% to 46,444 units (SEC Form 4)

Chief Financial Officer Ali Asif sold $631,872 worth of shares (14,203 units at $44.49) and exercised 12,000 shares at a strike of $15.68, decreasing direct ownership by 6% to 34,960 units (SEC Form 4)

$PTGX SEC Filings

Protagonist Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$PTGX Press Releases

Fastest customizable press release news feed in the world

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate

Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis

$PTGX Large Ownership Changes

This live feed shows all institutional transactions in real time.